

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drugs in Development, 2021

<https://marketpublishers.com/r/CF73D03F8AC2EN.html>

Date: September 2021

Pages: 202

Price: US\$ 3,500.00 (Single User License)

ID: CF73D03F8AC2EN

Abstracts

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drugs in Development, 2021

SUMMARY

According to the recently published report 'Complement C5 - Drugs In Development, 2021'; Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 43 molecules. Out of which approximately 39 molecules are developed by companies and remaining by the universities/institutes.

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

The report 'Complement C5 - Drugs In Development, 2021' outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications,

stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 13, 3, 5, 1, 16 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Immunology, Hematological Disorders, Gastrointestinal, Central Nervous System, Infectious Disease, Ophthalmology, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Oncology, Other Diseases, Respiratory and Undisclosed which include indications Paroxysmal Nocturnal Hemoglobinuria, Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Neuromyelitis Optica (Devic's Syndrome), Coronavirus Disease 2019 (COVID-19) Pneumonia, Autoimmune Disorders, Chronic Inflammation, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Kidney Disease (Nephropathy), Lupus Nephritis, Age Related Macular Degeneration, Bullous Pemphigoid, Dermatomyositis, Geographic Atrophy, Guillain-Barre Syndrome, Hidradenitis Suppurativa, IgA Nephropathy (Berger's Disease), Thrombotic Microangiopathy, Unspecified, Uveitis, Acute Lung Injury, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Antiphospholipid Syndrome, Atopic Keratoconjunctivitis, Bacterial Sepsis, Cardiovascular Inflammation, Choroidal Neovascularization, Community Acquired Pneumonia, Fibrosis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hematuria, Hemorrhagic Shock, Intermediate Uveitis, Juvenile Macular Degeneration (Stargardt Disease), Liver Transplant Rejection, Lung Adenocarcinoma, Lung Disease, Microscopic Polyangiitis (MPA), Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Posterior Uveitis, Primary Progressive Multiple Sclerosis (PPMS), Pyoderma Gangrenosum, Rheumatoid Arthritis, Sepsis, Septic Shock, Sickle Cell Disease With Vaso-Occlusive Crisis, Squamous Cell Carcinoma, Subarachnoid Hemorrhage, Sudoriferous (Sweat) Gland Disorders, Trauma, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome) and Unspecified Ophthalmological Disorders.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)

The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects

The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Projects

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Products under Development by Companies, 2021 (Contd..8)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Adienne Pharma & Biotech SA, 2021
Pipeline by Akari Therapeutics Plc, 2021
Pipeline by Alexion Pharmaceuticals Inc, 2021
Pipeline by Alnylam Pharmaceuticals Inc, 2021
Pipeline by Amgen Inc, 2021
Pipeline by Aptarion Biotech AG, 2021
Pipeline by Biocad, 2021
Pipeline by Biosion Inc, 2021
Pipeline by CANbridge Life Sciences Ltd, 2021
Pipeline by Chugai Pharmaceutical Co Ltd, 2021
Pipeline by Generium, 2021
Pipeline by ImmunAbs Inc, 2021
Pipeline by InflaRx NV, 2021
Pipeline by ISU ABXIS Co Ltd, 2021

Pipeline by IVERIC bio Inc, 2021
Pipeline by Navigen Inc, 2021
Pipeline by Novartis AG, 2021
Pipeline by NovelMed Therapeutics Inc, 2021
Pipeline by Prestige BioPharma Ltd, 2021
Pipeline by Ra Pharmaceuticals Inc, 2021
Pipeline by Rallybio Corp, 2021
Pipeline by Regeneron Pharmaceuticals Inc, 2021
Pipeline by Samsung Bioepis Co Ltd, 2021
Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, 2021
Pipeline by Staidson BioPharma Inc, 2021
Pipeline by Tasly Biopharmaceuticals Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/CF73D03F8AC2EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF73D03F8AC2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

